These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16850327)

  • 41. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
    Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
    Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression.
    Furuta K; Adachi K; Aimi M; Shimura S; Mikami H; Nishimura N; Ishimura N; Ishihara S; Naora K; Kinoshita Y
    Digestion; 2016; 93(2):111-20. PubMed ID: 26637113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
    Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
    Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
    Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
    Röhss K; Wilder-Smith C; Kilhamn J; Fjellman M; Lind T
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):345-54. PubMed ID: 17595892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
    Inamori M; Togawa J; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Shimamura T; Kubota K; Sakaguchi T; Saito S; Ueno N; Nakajima A
    J Gastroenterol; 2005 May; 40(5):453-8. PubMed ID: 15942709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
    Yi S; Lee H; Jang SB; Byun HM; Yoon SH; Cho JY; Jang IJ; Yu KS
    Aliment Pharmacol Ther; 2017 Aug; 46(3):337-346. PubMed ID: 28543183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated acidity and rabeprazole pharmacology.
    Gardner JD; Perdomo C; Sloan S; Hahne WF; Barth JA; Rodriguez-Stanley S; Robinson M
    Aliment Pharmacol Ther; 2002 Mar; 16(3):455-64. PubMed ID: 11876698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
    Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
    Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
    Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
    Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
    Sakurai Y; Mori Y; Okamoto H; Nishimura A; Komura E; Araki T; Shiramoto M
    Aliment Pharmacol Ther; 2015 Sep; 42(6):719-30. PubMed ID: 26193978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of the effect of PO administered acid suppressants on gastric pH in healthy cats.
    Ryan P; Odunayo A; Price J; Hecht S; Hillsman S; Galyon G; Steiner J; Tolbert MK
    J Vet Intern Med; 2020 Sep; 34(5):1879-1885. PubMed ID: 32885499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers.
    Hongo M; Kimpara T; Moriyama S; Ohara S; Sone S; Tamura T; Asaki S; Toyota T
    Tohoku J Exp Med; 1998 Sep; 186(1):43-50. PubMed ID: 9915106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
    Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.